N. Doan, L. Nguyen-Pham, C. Liang, Q. T. Duong
Energy for Health [16], 2017
The application of Concentrated Growth Factors (CGF) in oral and maxillofacial surgery (OMS) and, in general, in regenerative medicine is steadily increasing. The purpose of this study is to present a review and case reporting on the use of CGF for tissue regeneration in the oral maxillofacial region.
Literature search was carried out using Medline search and manual search using the keywords: “concentrated”, “growth factors”, “tissue engineering”, “regenerative medicine” and “blood”. The review followed the method recommended by PRISMA and included clinical studies with adequate information. Papers with lack of data were excluded. Additionally, authors’ experience on this topic was reported with the description of two relevant cases. In both patients, bony defects were filled with autologous fibrin rich CGF and synthetic alloplastic materials, and then treated with Mphi laser.
Results: There were no published data on the combined use of Mphi laser and CG Fin clinical applications in the OMS region. Two case reports on the surgical regenerative management of oral lesions CGF and Mphi laser were described. Postoperative recovery was uneventful. Laser was effective in reducing postoperative pain, swelling, bleeding, speech impairment, analgesic use, trismus and wound healing. There was no difference in wound healing after one and 3 months.
Conclusion: The innovative application of Concentrated Growth Factors (CGF) in combination with Mphi laser in Oral and Maxillofacial Region defectsproduced rapid improvement and minimized complications. The treatment is fairly simple and cost effective.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.